Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case–Control Study Using a National Health Screening Cohort

So Young Kim, Dae Myoung Yoo, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Joong Seob Lee () and Hyo Geun Choi ()
Additional contact information
So Young Kim: Bundang CHA Medical Center, Department of Otorhinolaryngology—Head and Neck Surgery, CHA University, Seongnam 13488, Korea
Dae Myoung Yoo: Hallym Data Science Laboratory, Hallym University College of Medicine, Anyang 14066, Korea
Mi Jung Kwon: Department of Pathology, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Korea
Ji Hee Kim: Department of Neurosurgery, Hallym University College of Medicine, Anyang 14068, Korea
Joo-Hee Kim: Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Korea
Joong Seob Lee: Department of Otorhinolaryngology—Head and Neck Surgery, Hallym University College of Medicine, Anyang 14068, Korea
Hyo Geun Choi: Bundang CHA Medical Center, Department of Otorhinolaryngology—Head and Neck Surgery, CHA University, Seongnam 13488, Korea

IJERPH, 2022, vol. 19, issue 16, 1-13

Abstract: The present nested case–control study evaluated the impact of previous proton pump inhibitor (PPI) prescription on the risk of benign paroxysmal positional vertigo (BPPV). A ≥40-year-old Korean population was included. A total of 34,441 patients with BPPV was matched with 137,764 comparison participants for demographic and socioeconomic factors. Previous histories of PPI use and PPI prescription dates were compared between the BPPV and comparison groups. The odds ratios (ORs) with 95% confidence intervals (CIs) of PPI use for BPPV were calculated using a logistic regression. The demographic and socioeconomic factors and comorbidities were adjusted in the adjusted model. Both current and past PPI users were associated with higher odds for BPPV than non-PPI users (adjusted OR (aOR) = 3.57, 95% CI = 3.33–3.83, and p < 0.001 for current PPI users and aOR = 1.76, 95% CI = 1.64–1.89, and p < 0.001 for past PPI users). In addition, longer dates of PPI use were related to higher odds for BPPV (aOR (95% CI) = 1.95 [1.81–2.10] for ≥1 day and <30 days of PPI prescription, <2.88 [2.68–3.10] for ≥30 days and <365 days of PPI prescription, and <3.45 [3.19–3.73] for ≥365 days of PPI prescription). PPI use was linked with an elevated risk of BPPV in the adult population. The odds for BPPV were higher in patients with a longer duration of PPI use.

Keywords: proton pump inhibitor; benign paroxysmal positional vertigo; risk factors; cohort studies (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/16/10280/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/16/10280/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:16:p:10280-:d:891620

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().